Exosomal RNA: A Novel Signature Guide for Prostate Cancer Proton Therapy

外泌体 RNA：前列腺癌质子治疗的新特征指南

基本信息

批准号：
10681297
负责人：
Simone Olivia Heyliger
金额：
$ 8.76万
依托单位：
HAMPTON UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-09-22 至 2025-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10681297
关键词：
Achievement African American population Area Biological Markers Biopsy Blood Blood specimen Body Fluids Cancer Patient Cells Cerebrospinal Fluid Cessation of life Clinical Collaborations DNA Data Decision Making Detection Development Disease European Evaluation Excision Feasibility Studies Future Genes Genetic Genomics Goals Grant Health Historically Black Colleges and Universities Human Joints Legal patent Lipids Magnetic Resonance Imaging Malignant Neoplasms Malignant neoplasm of prostate Measurement Measures Messenger RNA Modality Molecular Monitor Neoplasm Metastasis Newly Diagnosed Normal Cell Operative Surgical Procedures Outcome Outcomes Research Patients Physicians Preparation Process Prostate Prostate-Specific Antigen Prostatectomy Prostatic Proteins RNA Radiation Monitoring Radiation therapy Radical Prostatectomy Recurrence Research Research Infrastructure Rest Risk Risk Assessment Saliva Sampling Site Testing Time Study Tissues Toxic effect Universities Urine Urologic Oncology Urology Vesicle Virginia Work anticancer research cancer genomics clinical decision-making cohort detection method exosome extracellular vesicles follow-up improved liquid biopsy medical schools men microvesicles neoplastic cell non-invasive monitor novel particle prognostic prostate biopsy proton therapy recruit response response biomarker serum PSA specific biomarkers tool trafficking treatment response tumor tumor microenvironment unnecessary treatment

项目摘要

Project Summary / Abstract Proton therapy (PT) is a form of radiation therapy used to treat prostate cancer patients that can be an alternative to surgery. While PT is thought to risk less toxicity than conventional radiation therapy, much about PT is still not understood. To help serve their local area of tidewater Virginia, which has one of the highest rates of prostate cancer in the world, especially in African-Americans, Hampton University (HU), a Historically Black University, has opened the Hampton University Proton Therapy Institute. To help build the research capacity at HU, leveraging their clinical expertise in proton therapy, the Icahn School of Medicine at Mount Sinai (ISMMS) and HU propose this joint project aimed at developing a noninvasive biomarker for response to PT. The team at ISMMS will bring their expertise in genomics and exosome profiling, a noninvasive way to measure particles that are thought to shed from the tumor, to this project and in the process help build the research capacity at HU. The research goal of this project is to determine changes in the exosomal RNA (exoRNA) profile of exosomes taken from prostate cancer patients before and after radiotherapy with PT. All aims of the study use patient samples collected at the HUPTI by the HU team. In aim 1, we will ask if an exosomal signature of radical prostatectomy shows similar changes before and after PT. In aim 2, to determine if there are specific changes in the mRNA profile in response to PT, we will globally profile RNA isolated from exosomes before and after PT. In aim 3, to continue to build this project in preparation for a future collaborative R01 submission, we will recruit additional patients from HUPTI to this study and obtain blood specimens before, during, and after PT. At the end of the study time period, our scientific achievement will have been to determine what changes in the RNA profile of exosomes can be observed in response to PT. This will be important preliminary data demonstrating the utility of exosomes for noninvasive monitoring of PT. More importantly, through this collaborative partnership between ISMMS and HU, we will have enhanced the research infrastructure of HU in a way that will allow HU to pursue further research both jointly with ISMMS and independently building on their clinical expertise in proton therapy.

项目概要/摘要质子疗法 (PT) 是一种用于治疗前列腺癌患者的放射疗法，可以作为一种治疗方法。手术的替代方案。虽然 PT 被认为比传统放射治疗的毒性风险更小，但 PT还是没明白。为了帮助服务弗吉尼亚州当地的潮水区，该地区是潮汐最高的地区之一汉普顿大学 (HU)，历史上的一所研究机构，研究了世界范围内前列腺癌的发病率，尤其是非裔美国人的发病率布莱克大学开设了汉普顿大学质子治疗研究所。帮助开展研究 HU 的能力，利用他们在质子治疗方面的临床专业知识，蒙特伊坎医学院西奈半岛 (ISMMS) 和 HU 提出了这个联合项目，旨在开发一种非侵入性生物标志物来应对 PT。 ISMMS 团队将带来他们在基因组学和外泌体分析方面的专业知识，这是一种非侵入性方法测量被认为从肿瘤中脱落的颗粒，到这个项目，并在此过程中帮助建立 HU 的研究能力。该项目的研究目标是确定外泌体 RNA 的变化 (exoRNA) 取自前列腺癌患者在 PT 放疗前后的外泌体图谱。全部该研究的目的是使用 HU 团队在 HUPTI 收集的患者样本。在目标 1 中，我们将询问是否根治性前列腺切除术的外泌体特征在 PT 前后显示出相似的变化。在目标 2 中，确定 mRNA 谱是否因 PT 而发生特定变化，我们将全面分析 RNA 在 PT 之前和之后从外泌体中分离。在目标 3 中，继续建设该项目，为未来合作 R01 提交，我们将从 HUPTI 招募更多患者参与本研究并获得 PT 之前、期间和之后的血液样本。在研究期结束时，我们的科学成果我们的目标是确定外泌体 RNA 谱在 PT 反应中可以观察到哪些变化。这将是重要的初步数据，证明外泌体在 PT 无创监测中的实用性。更重要的是，通过 ISMMS 和 HU 之间的合作伙伴关系，我们将增强 HU 的研究基础设施将使 HU 能够与 ISMMS 和独立地建立在质子治疗方面的临床专业知识。